India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Therefore, Sanofi's partnership with Sudair Pharma aims to address this gap and increase access to effective care for people ...

This summary highlights a series of health-related developments including HIV contraction in Brazilian transplant patients, ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Gan & Lee Pharmaceuticals (SHE: 603087) reported positive Phase II trial results for its diabetes drugs GZR18, GZR4, and ...

Saxenda is an older drug of the same GLP-1 drug class as the company’s popular Ozempic diabetes treatment and ... Antoine Armand wants guarantees from Sanofi that production of its popular ...

medication regimens and sensor devices. Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott ...

Today, there’s an immunoscience renaissance happening, and Sanofi is pushing medical research in this field forward at a much ...

Novo Nordisk May Proceed with Its Ozempic Suit Against DCA Pharmacy. A Tennessee federal court denied DCA Pharmacy’s motion ...

Although the drug is indicated for type 2 diabetes, it has been used off-label ... Meanwhile, Dupixent from Regeneron and Sanofi is set to bring in $13.5B this year, up from $11.6B in 2023.